Patterson-UTI (PTEN): The Q2 Recovery Story the Market Keeps Ignoring

The data tells a clearer story than the recent headlines suggest. Patterson-UTI reported Q2 adjusted EBITDA of $232 million on $1.23 billion in revenue — a 10% sequential improvement with pricing momentum across all three operating segments. The GAAP net loss of roughly $20 million was driven almost entirely by a non-cash write-down from its Colombia exit, not by deteriorating operations. The stock's 5.8% five-day pullback and the "narrower loss" framing in competitor coverage miss the more important question: after climbing 61% year-to-date from $5.10 to around $9.87, how much of the recovery has already been baked in, and does the remaining peer discount still justify a position?

The operating picture has turned the corner. Q2 saw an average of 92 contract drilling rigs operating in the U.S., and management guides for approximately 100 rigs in Q3, exiting the quarter above that level. New drilling contracts are securing day rates 10% to 15% above Q1, with upgraded rigs commanding additional premiums. The completion services segment — where pricing had fallen an estimated 30% or more over a three-year downturn — is now seeing a recovery as natural gas-powered frac capacity runs near full utilization. Drilling products hit a record $91 million in quarterly revenue, the highest since the Ulterra acquisition in 2023. Q3 segment guidance projects adjusted gross profit of approximately $145 million in drilling, $140 million in completions, and $40 million in products — all above Q2 levels. This is an accelerating cycle, not a plateau.

From a cash flow perspective, the trailing twelve-month operating cash flow stands at $733 million against $556 million in capital expenditures, yielding $178 million in trailing free cash flow. That's down 47% year-over-year, which reflects the trough rather than the current trajectory. Management guided for net capex of approximately $600 million for the full year, meaning capex intensity is moderating as revenue accelerates. They expect free cash flow to improve meaningfully in the second half of 2026 and into 2027. Working capital was a short-term drain in the first half due to rapid activity acceleration, which is a cyclical timing effect rather than a structural problem. Once the build-out stabilizes, that drag reverses.

Now let's talk about the balance sheet, because this is where the market's recent reaction has some basis. Total debt stands at $2.3 billion against roughly $200 million in cash. The $500 million in 6.05% notes due 2036, issued in May, refinanced the cheaper 3.95% notes due 2028. The coupon jumped 210 basis points to extend maturities by eight years, which pushes the next maturity wall to 2029. Interest expense runs approximately $20 million per quarter. Debt-to-equity sits at 39.7%, and there's a $500 million revolving credit facility with $0 drawn. Fitch rates the senior unsecured notes at BBB-. The refinancing raises the interest burden but eliminates a near-term wall. With operating cash flow of $733 million annually, quarterly interest of $20 million is covered roughly 36 times on a cash basis. That's not a solvency concern.

The valuation is where the real question lives. PTEN trades at 5.76 times EV/EBITDA on a trailing basis, with an enterprise value of $4.8 billion against a $3.8 billion market cap. Noble trades at 8.69 times EV/EBITDA. Helmerich & Payne trades at 6.49 times. Valaris trades at 15.76 times. The discount to Noble — the closest peer in scale and business mix — is roughly 34%. Even relative to Helmerich & Payne, PTEN is meaningfully cheaper. A re-rating to just the Helmerich level would imply roughly 13% upside from current prices; a move to Noble's multiple would imply approximately 51% upside. The price-to-cash-flow multiple of 5.1 times is equally compressed, suggesting the market is still pricing PTEN as if its Q1 capex-heavy, loss-making phase is the steady state rather than a trough that's already been left behind.

The dividend adds a layer of income context. The quarterly payout of $0.10 per share translates to a trailing yield of 3.64% and a forward yield of 3.24%. Management has committed to returning at least 50% of adjusted free cash flow to shareholders, and they expect adjusted free cash flow to more than cover 2026 dividend payments. The 21-year consecutive dividend history gives this income stream durability that most energy services companies can't match.

While it's true that the stock has already climbed 61% year-to-date and the margin of safety has narrowed from where it stood six months ago at $5, I would argue that the market's recent 5.8% pullback is a disproportionate reaction to near-term noise — a Colombia write-down, a refinanced note at a higher coupon, and whatever shelf registration filing triggered dilution headlines — layered onto a stock whose operating trajectory is pointing in the opposite direction. The adjusted EBITDA of $232 million in Q2, with all segments beating mid-quarter guidance and pricing accelerating, doesn't belong to a company in distress. It belongs to a company coming out of a cycle trough.

Even if the rig count stalls below 100 or day rate recovery proves slower than management's 10% to 15% guidance, the underlying math still works. At current prices, you're buying an annualized run rate of roughly $928 million in adjusted EBITDA for less than 5.3 times on an EV basis. The balance sheet can service its debt. The dividend is covered. And the peer discount remains one of the widest in the drilling services sector.

There's a real counterpoint worth acknowledging. PTEN's free cash flow fell 47% year-over-year, trailing revenue growth came in at just 0.7%, and the company remains GAAP-unprofitable with negative returns on invested capital. If the cycle reverts or capex needs stay elevated while pricing gains erode, the current price could prove adequate compensation. But the data I'm seeing — sequential revenue acceleration, pricing recovering across all three segments, rigs climbing, and working capital drag expected to reverse — points to a company in the early recovery phase, not a mature operator hitting a wall. The market still seems to be pricing it like the latter.

All things considered, the cash flow inflection is underway, the balance sheet is manageable, the dividend carries a 21-year track record, and the EV/EBITDA discount to peer averages still creates meaningful upside. The stock is not the screaming bargain it was at $5, but it's not priced for perfection either. I reaffirm my Buy rating.